Zusammenfassung
Hintergrund: Die TNF-Antagonisten Infliximab, Adalimumab und Etanercept haben eine zunehmende
Bedeutung in der Behandlung entzündlich-rheumatischer Erkrankungen: der rheumatoiden
Arthritis (RA), der Psoriasisarthritis (PsA) und der ankylosierenden Spondylitis (AS).
Trotzdem haben die noch relativ hohen Kosten nicht nur in Deutschland zu einer im
europäischen Vergleich restriktiven Verordnungspraxis unter der Vorstellung besserer
Wirtschaftlichkeit geführt. Ob eines der Präparate insgesamt kostengünstiger als die
anderen ist, ist letztlich ungeklärt, zumal die unterschiedliche Verabreichung und
Dosierung die Berechnung und Bewertung erschwert. Ziel und Methoden: Berechnung und Vergleich der Kosten der TNF-Blocker bei den verschiedenen rheumatischen
Erkrankungen und Analyse der klinischen Situation bei der Indikationsstellung. Ergebnisse: Die TNF-Blocker weisen einige pharmakologische Unterschiede auf. Die Kosten sind
ebenfalls different, dies liegt zum großen Teil an der Abhängigkeit von Dosis und
Körpergewicht. In einem begrenzten Bereich bestehen zudem Anhaltspunkte für ein Dosis/Wirkungsverhältnis.
Zwar sind die Ansprechraten insgesamt vergleichbar, es gibt aber Unterschiede in der
Wirksamkeit bei den einzelnen Symptomen bzw. Erkrankungen. Das Verordnungsverhalten
entspricht nicht dem Muster in den klinischen Studien. Über erfolgreiche Therapiewechsel
untereinander wurde berichtet. Die Therapie-Adhärenz ist nicht unterschiedlich zwischen
den Präparaten. Das Nebenwirkungsspektrum unterscheidet sich wenig. Schlussfolgerung: Es besteht keine Veranlassung, ein Präparat grundsätzlich zu bevorzugen, da es unterschiedliche
Kostenvor- und -nachteile für die Präparate gibt.
Abstract
Background: The TNF-antagonists infliximab, adalimumab and etanercept are gaining increasing
importance in the treatment of inflammatory rheumatic diseases such as rheumatoid
arthritis (RA), psoriatic arthritis (PA) and ankylosing spondylitis (AS). Even so,
in a European comparison the relatively high costs have led rather to a restrictive
prescription practice under the presumption of better economics not only in Germany.
Whether or not these preparations are on the whole economically more favourable than
others is still not clarified, especially because the different forms of administration
and dosages make calculation and evaluation difficult. Objective and Methods: The aim of this study is to calculate and compare the costs of TNF-blockers in various
rheumatic diseases and analyse the clinical situation for their indication. Results: The TNF-blockers exhibit some pharmacological differences. The costs also differ,
this is mainly due to the dependence of the dose on body weight. To a limited extent
there is also some evidence for a dose-efficacy relationship. Although the response
rates are similar, there are differences in efficacy with regard to individual symptoms
and diseases. Prescription practice does not correspond to the pattern of clinical
studies. Successful cross-over therapies have been reported. Therapy adherence does
not differ between the preparations. The spectrum of side effects shows only minor
variations. Conclusions: There is no reason to specifically favour one product since the all have differing
cost advantages and disadvantages.
Schlüsselwörter
TNF-Antagonisten - Infliximab - Adalimumab - Etanercept - rheumatische Erkrankungen
- Kostenvergleich
Key words
TNF-antagonists - Infliximab - Adalimumab - etanercept - inflammatory rheumatic diseases
- cost comparisons
Literatur
- 1
Manger B, Komission Pharmakotherapie der DGRh .
Stellungnahme zur Präparatewahl bei TNF-Inhibitoren.
Z Rheumatol.
2005;
64
88-89
- 2
Furst D E, Breedveld F C, Kalden J R. et al .
Updated consensus statement on biological agents for the treatment of rheumatic diseases,
2006.
Ann Rheum Dis.
2006;
65 (Suppl 3)
iii2-iii15
- 3
Goekoop-Ruiterman Y P, Vries-Bouwstra J K, Allaart C F. et al .
Clinical and radiographic outcomes of four different treatment strategies in patients
with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Arthritis Rheum.
2005;
52 (11)
3381-3390
- 4
Leonardi C L, Powers J l, Matheson R T. et al .
Etanercept as a monotherapy in patients with psoriasis.
N Engl J Med.
2003;
349 (21)
2041-2022
- 5
Papp K A, Tyring S de, Lahfa M. et al .
A global phase III randomized controlled trial of etanercept in psoriasis: safety,
efficacy, and effect of dose reduction.
Br J Dermatol.
2005;
152 (6)
1304-1312
- 6
Reich K, Nestle F O, Papp K. et al .
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase
III multicentre, double-blind trial.
Lancet.
2005;
366 (9494)
1333-1335
- 7
Gordon K B, Langley R G, Leonardi C. et al .
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis:
double-blind, randomized controlled trial and open-label extension study.
J Am Acad Dermatol.
2006;
55 (4)
598-606 [Epub 10.8.2006]
- 8
Edrees A F, Misra S N, Abdou N I.
Anti-tumor therapy in rheumatoid arthritis: correlation of TNFa necrosis factor (TNF)
serum levels with clinical response and benefit from changing dose or frequence of
infliximab infusion.
Clin Exp Rheumatol.
2005;
23 (4)
469-474
- 9
Siridopoulos P, Bertsias G, Kritikos H D. et al .
Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease
Activity Score: dose adjustments are common but not always sufficient to assure sustained
benefit.
Ann Rheum Dis.
2004;
63 (2)
144-148
- 10
Ollendorf D A, Massarotte E, Birbara C. et al .
Frequence, predictors and economic impact of upward dose adjustment of infliximab
in managed care patients with rheumatoid arthritis.
J Manag Care Pharm.
2005;
11 (5)
383-393
- 11
Gossec L, Le Henanff A, Breban N. et al .
Continuation of treatment with infliximab in ankylosing spondylitis: 2 year open follow
up.
Rheumatology (Oxford).
2006;
45 (7)
859-862
- 12
Durez P, Van den Bosch F, Corluy L. et al .
A dose adjustment in patients with rheumatoid arthritis not optimally responding to
a standard dose of infliximab of 3 mg/kg KG every 8 weeks can be effective: a Belgian
prospective study.
Rheumatology (Oxford).
2005;
44 (4)
465-468
- 13
Zink A, Listing J, Strangfeld A. et al .
Dosisanpassung bei Patienten mit rheumatoider Arthritis unter Therapie mit Infliximab
in der rheumatologischen Versorgung in Deutschland. Ergebnisse aus dem Biologika-Register
RABBIT.
Z Rheumatol.
2006;
Mar, 14 [Epub ahead of print]
- 14
Zink A, Strangfeld A, Schneider M. et al .
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational
cohort study: Comparison of patients according to their eligibility for major randomized
clinical trials.
Arthritis Rheum.
2006;
54 (11)
3399-3407 [Epub ahead of print]
- 15
Collantes-Estevez E, Munoz-Villanueva M C, Zarco P. et al .
Effectivness of reducing infliximab dose interval in non-responder patient with the
refractory spondyloarthropathies. An open extension of a multicenter study.
Rheumatology (Oxford).
2005;
44 (12)
1555-1558
- 16
Siridopoulos P, Kritikos H D, Siakka P. et al .
Low dose infliximab is inadequate in most patients with spondyloarthropathies.
Clin Exp Rheumatol.
2005;
23 (4)
513-516
- 17
Keeling S, Oswald A, Russel A S. et al .
Prospective observational analysis of the efficacy ad safety of low dose (3 mg/kg)
infliximab in ankylosing spondylitis: 4-yr follow up.
J Rheumatol.
2006;
33
558-561
- 18
Jois R N, Leeder L, Gibb A. et al .
Low dose infliximab treatment for ankylosing spondylitis - clinically and cost effective.
Rheumatology (Oxford).
2006;
May 16 [Epub ahead of print]
- 19
Wick M C, Ernestam S, Linblad S. et al .
Adalimumab (Humira) restores clinical response in patients with secondary loss of
efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE
registry at Karolinska University Hospital.
Scand J Rheumatol.
2005;
34 (5)
353-358
- 20
Cohen G, Courvoisier N, Cohen J D. et al .
The efficience of switching from infliximab to etanercept and vice-versa in patients
with rheumatoid arthritis.
Clin Exp Rheumatol.
2005;
23 (6)
795-800
- 21
Solau-Gervais E, Laxenaire N, Cortet B. et al .
Lack of efficacy of a third tumor necrosis factor-alpha antagonist after failure of
a soluble receptor and a monoclonal antibody.
Rheumatology (Oxford).
2006;
45 (9)
1121-1124
- 22
Hansen K E, Hildebrand J P, Gnvese M C. et al .
The efficacy of switching from etanercept to infliximab in patients with rheumatoid
arthritis.
J Rheumatol.
2004;
31 (6)
1098-0102
- 23
Sanmarti R, Gomez-Puerta J A, Rodriguez-Cros J R. et al .
Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab
[Abstract].
Med Clin (BArc).
2004;
122 (9)
321-324
- 24
Gomez-Reino JJ, Carmona L; BIOBADSER Group .
Switching TNF antagonists in patients with chronic arthritis: an observational study
of 488 patients over a four year period.
Arthritis Res Ther.
2006;
8 (1)
R29 [Epub 6.1.2006]
- 25
Delaunay C, Farrenq V, Marini-Portugal A. et al .
Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic
arthritis: preliminary data.
J Rheumatol.
2005;
32 (11)
2183-2185
- 26
Wolfe F, Michaud K, Anderson J. et al .
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab
therapy.
Arthritis Rheum.
2004;
50 (2)
372-379
- 27
Askling J, Fored C M, Brandt L. et al .
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with
tumor necrosis factor antagonists in Sweden.
Arthritis Rheum.
2005;
52 (7)
1986-1992
- 28
Gomez-Reino J J, Carmona L, Valverde V R. et al .
Treatment of rheumatoid arthritis with TNF inhibitors may predispose to significant
increase in tuberculosis risk: a multicenter active-surveillance report.
Arthritis Rheum.
2003;
48 (8)
2122-2127
- 29
Carmona L, Gomez-Reino J J, Rodriguez-Valverde V. et al .
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection
in patients treated with tumor necrosis factor antagonists.
Arthritis Rheum.
2005;
52 (6)
1766-1772
- 30
Listing J, Strangfeld A, Kary S. et al .
Infections in patients with rheumatoid arthritis treated with biologic agents.
Arthritis Rheum.
2005;
52 (11)
3403-3412
- 31
Dixon W G, Watson K, Lunt M. et al .
Rates of serious infection, including site-specific and bacterial intracellular infection,
in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results
from the British Society for Rheumatology Biologics Register.
Arthritis Rheum.
2006;
54 (8)
2368-2376
- 32
Wolfe F, Michaud K.
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis
factor therapy in 18,572 patients.
Arthritis Rheum.
2004;
50 (6)
1740-1751
- 33
Baecklund E, Iliadou A, Askling J. et al .
Association of chronic inflammation, not its treatment, with increased lymphoma risk
in rheumatoid arthritis.
Arthritis Rheum.
2006;
54 (3)
692-701
- 34
Wolfe F, Michaud K.
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor
necrosis factor therapy.
Am J Med.
2004;
116 (5)
305-311
Prof. Dr. med. J. Braun
Rheumazentrum Ruhrgebiet, St.-Josefs-Krankenhaus
Landgrafenstr. 15
44652 Herne
eMail: braun@rheumazentrum-ruhrgebiet.de
